Table 1.
Baseline clinical and laboratory parameters.
| Parameters | All patients n = 210 |
Group 1 BAV n = 70 |
Group 2 TAV n = 140 |
P-value |
|---|---|---|---|---|
| Age (years) | 75.9 ± 9.0 | 72.0 ± 9.1 | 77.9 ± 8.3 | <0.001 |
| Female n (%) | 102 (48.6) | 30 (42.9) | 72 (51.4) | 0.241 |
| BMI (kg/m2) | 27.1 ± 4.7 | 27.2 ± 4.8 | 27.0 ± 4.6 | 0.801 |
| NYHA n (%) - 2 - 3 - 4 |
64 (30.5) 123 (58.5) 23 (11.0) |
20 (28.6) 42 (60.0) 8 (11.4) |
44 (31.4) 81 (65.9) 15 (10.7) |
0.711 |
| DM n (%) | 66 (31.4) | 27 (38.6) | 39 (27.9) | 0.115 |
| HT n (%) | 171 (81.4) | 53 (75.7) | 118 (84.3) | 0.132 |
| HL n (%) | 112 (53.3) | 35 (50.0) | 77 (55.0) | 0.494 |
| Current smoker n (%) | 58 (27.6) | 18 (25.7) | 40 (28.5) | 0.684 |
| Previous PCI n (%) | 45 (21.4) | 16 (22.9) | 29 (20.7) | 0.721 |
| Previous CABG n (%) | 55 (26.2) | 19 (27.1) | 36 (25.7) | 0.824 |
| Previous MI n (%) | 27 (12.9) | 12 (17.1) | 15 (10.7) | 0.190 |
| Moderate to severe COPD n (%) | 87 (41.4) | 44 (48.6) | 53 (37.9) | 0.315 |
| AF n (%) | 46 (21.9) | 14 (20.0) | 32 (22.9) | 0.637 |
| Stroke n (%) | 14 (6.7) | 3 (4.3) | 11 (7.9) | 0.328 |
| CAD - Normal - Nonobstructive |
60 (28.6) 90 (42.9) |
21 (30.0) 32 (45.7) |
39 (27.9) 58 (41.4) |
0.057 |
| Medication n (%) - RAS blocker - Statin - Beta blocker - ASA - OAC |
153 (72.8) 106 (50.4) 80 (38.1) 151 (72.9) 49 (23.7) |
45 (64.2) 28 (40.0) 23 (32.8) 54 (79.4) 12 (17.6) |
108 (77.1) 78 (55.7) 57 (40.7) 97 (69.8) 37 (26.7) |
0.135 |
BMI: Body Mass Index; NYHA: New York Heart Association; DM: Diabetes Mellitus; HT: Hypertension; PCI: Percutaneous Coronary Intervention, CABG: Coronary artery Bypass Grafting, MI: Myocardial Infarction, COPD: Chronic Obstructive Pulmonary Disease, AF: Atrial Fibrillation; CAD: Coronary Artery Disease; RAS: Renin-angiotensin-system; ASA: Acetyl salicylic acid; OAC: Oral anticoagulant